- Company to further expand its DECODE™ discovery platform, accelerate multiple oncology clinical programs, and advance discovery programs in oncology, autoimmune disorders, infectious disease, and other serious diseasesCAMBRIDGE, Mass. (BUSINESS WIRE) Repertoire Immune Medicines, a clinical-stage biotech company.
Repertoire Immune Medicines Secures $189M Financing to Advance Pipeline Programs and Discovery Platform Directed at Cellular Immune Targets yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Repertoire Immune Medicines to Present Data from Autologous T Cell Therapy PRIME IL-15 (RPTR-147) in Advanced or Metastatic Solid Tumor Cancers
April 9, 2021 GMT
CAMBRIDGE, Mass. (BUSINESS WIRE) Apr 9, 2021
Repertoire Immune Medicines, a clinical-stage biotech company decoding the immune synapse to create novel immune therapies for cancer, immune disorders, infectious disease, and other serious diseases, today announced the presentation of translational data obtained from applying its proprietary antigen-specific TCR-MHC DECODE™ platform in its Phase 1 trial evaluating PRIME IL-15 (RPTR-147) in patients with advanced or metastatic solid tumor cancers. The data will be presented at the American Association of Cancer Research (AACR) Virtual Meeting Week 1, taking place April 10-15, 2021. PRIME IL-15, the company’s lead investigational therapy, is a novel non-genetically modified,